SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (2371)10/16/1997 11:07:00 PM
From: Oliver & Co   of 6136
 
Izzy, I am going to look tomorrow in my office for some recent studies that have been published having to do with markers in the CD8 cells, one is HLA-DR and another is a CD34? marker on the CD8 cell surface. These markers appear to be better predictors of disease progression than CD4, or viral load, independently or toguether.
It is interesting, on patients who have had CMV Retinitis, it is the drop in CD8 cells that is a bad prognostic factor for reactivation, and not the CD4 count (as per Janet Davis,MD at Bascom Palmer Eye Institute, a leading CMV Retinitis investigator)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News